Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $640
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $580 to $640.
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $580 to $640.